Biosimilar Infliximab Deemed Safe, Effective in Pediatric Patients With IBD - The Center for Biosimilars

Researchers found that an infliximab biosimilar was as safe and effective as the reference product (Remicade) in pediatric patients with inflammatory bowel disease. However, more studies on adalimumab biosimilars in pediatric patients are needed.

According to a review published in Biologics, studies confirmed that the infliximab biosimilar CT-P13 (Inflectra, Remsima) is as safe and effective as the reference product (Remicade) in both treatme… [+5062 chars]

full article...